Recent Updates
Recently added Catalysts
AZN Neutral Sentiment Score: 50/100

SECURITIES AND EXCHANGE COMMISSION

Key Takeaway: AstraZeneca PLC submitted a report to the Securities and Exchange Commission for February 2024 under Rule 13a-16. This document includes information related to its foreign issuer status and compliance with the Securities Exchange Act of 1934. Adrian Kemp, the Company Secretary, signed the report on February 20, 2024. The report indicates the filing of required annual financial reports.

Market Sentiment Analysis

Full Press Release Details

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of February 2024
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
ANNUAL FINANCIAL REPORT
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: 20 February 2024
By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary

Frequently Asked Questions

What is the purpose of this report?

This report is a submission by AstraZeneca under the Securities Exchange Act.

Who is the registrant of this report?

The registrant of this report is AstraZeneca PLC.

What is the commission file number for this report?

The commission file number is 001-11960.

When was this report signed?

The report was signed on 20 February 2024.

Who signed the report?

The report was signed by Adrian Kemp, the Company Secretary.

Last updated: Feb 20, 2024